An Update of Patents, Preclinical and Clinical Outcomes of Lipid Nanoparticulate Systems

E-ISSN： 1873-4286|23|43|6602-6612

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.43, 2018-02, pp. : 6602-6612

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results

Current Drug Targets, Vol. 15, Iss. 12, 2014-11 ,pp. : 1107-1120

Bentham Science Publishers

Access to resources Recommend Favorite

From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease

By S. Brocardo Patricia M. Gil-Mohapel Joana

Current Psychopharmacology, Vol. 2, Iss. 2, 2013-05 ,pp. : 113-131

Bentham Science Publishers

Access to resources Recommend Favorite

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 –– 10)

By Cheung Chun Hei Antonio Coumar Mohane Selvaraj Chang Jang-Yang Hsieh Hsing-Pang

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 857-884

Informa Healthcare

Access to resources Recommend Favorite

Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities

Current Drug Metabolism, Vol. 10, Iss. 8, 2009-10 ,pp. : 861-874

Bentham Science Publishers

Access to resources Recommend Favorite

Nanoparticulate Drug Delivery Systems

By Senior Judy

Drug Development and Industrial Pharmacy, Vol. 34, Iss. 1, 2008-01 ,pp. : 116-116

Informa Healthcare

Access to resources Recommend Favorite